Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Lapatinib Plus Trastuzumab	2,093
Overall Study	STARTED	Trastuzumab Followed by Lapatinib	2,091
Overall Study	STARTED	Lapatinib	2,100
Overall Study	STARTED	Trastuzumab	2,097
Overall Study	Safety Population	Lapatinib Plus Trastuzumab	2,061
Overall Study	Safety Population	Trastuzumab Followed by Lapatinib	2,076
Overall Study	Safety Population	Lapatinib	2,056
Overall Study	Safety Population	Trastuzumab	2,076
Overall Study	COMPLETED	Lapatinib Plus Trastuzumab	1,132
Overall Study	COMPLETED	Trastuzumab Followed by Lapatinib	1,184
Overall Study	COMPLETED	Lapatinib	1,179
Overall Study	COMPLETED	Trastuzumab	1,192
Overall Study	NOT COMPLETED	Lapatinib Plus Trastuzumab	961
Overall Study	NOT COMPLETED	Trastuzumab Followed by Lapatinib	907
Overall Study	NOT COMPLETED	Lapatinib	921
Overall Study	NOT COMPLETED	Trastuzumab	905

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00490139/flow